Profile data is unavailable for this security.
About the company
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
- Revenue in USD (TTM)897.54m
- Net income in USD-188.66m
- Incorporated2019
- Employees4.79k
- LocationEvotec SEEssener Bogen 7HAMBURG 22419GermanyDEU
- Phone+49 40560810
- Fax+49 4 056081222
- Websitehttps://www.evotec.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Septerna Inc | 22.05m | -58.81m | 1.23bn | 75.00 | -- | 3.16 | -- | 55.85 | -1.51 | -1.51 | 0.5304 | 8.71 | 0.0565 | -- | 4.98 | 293,933.30 | -15.06 | -- | -16.99 | -- | -- | -- | -266.77 | -- | -- | -- | 0.00 | -- | 611.92 | -- | -12,762.79 | -- | -- | -- |
| Taysha Gene Therapies Inc | 6.31m | -99.93m | 1.25bn | 73.00 | -- | 5.69 | -- | 197.52 | -0.3328 | -0.3328 | 0.0212 | 0.7995 | 0.0254 | -- | -- | 86,438.36 | -40.23 | -70.59 | -45.55 | -88.39 | -- | -- | -1,583.66 | -2,287.96 | -- | -- | 0.1899 | -- | -46.07 | -- | 19.96 | -- | -- | -- |
| AtaiBeckley Inc | 3.02m | -154.19m | 1.30bn | 54.00 | -- | 5.37 | -- | 428.91 | -0.8136 | -0.8136 | 0.0161 | 0.6644 | 0.0138 | -- | 0.3354 | 55,981.48 | -70.56 | -45.69 | -77.07 | -50.03 | -- | -- | -5,104.20 | -2,658.81 | -- | -- | 0.00 | -- | -1.91 | -- | -271.09 | -- | 37.97 | -- |
| Evotec SE (ADR) | 897.54m | -188.66m | 1.31bn | 4.79k | -- | 1.31 | -- | 1.46 | -0.5313 | -0.5313 | 2.53 | 2.67 | -- | -- | -- | -- | -- | -- | -- | -- | 10.82 | 20.83 | -21.02 | -15.88 | 2.03 | -2.54 | 0.3772 | -- | 1.99 | 12.29 | -133.67 | -- | 32.89 | -- |
| Monte Rosa Therapeutics Inc | 181.54m | 20.95m | 1.31bn | 147.00 | 71.52 | 4.50 | 44.63 | 7.20 | 0.2506 | 0.2506 | 2.20 | 3.98 | 0.4685 | -- | 65.30 | 1,354,761.00 | 5.41 | -33.14 | 6.24 | -39.19 | -- | -- | 11.54 | -563.84 | -- | -- | 0.00 | -- | -- | -- | 46.29 | -- | 23.56 | -- |
| Azenta Inc | 594.95m | 28.69m | 1.32bn | 3.00k | 45.77 | 0.768 | 15.43 | 2.22 | 0.6252 | -1.26 | 12.98 | 37.26 | 0.2891 | 4.03 | 4.00 | 198,317.70 | 1.39 | -0.3901 | 1.57 | -0.4328 | 44.59 | 45.32 | 4.82 | -1.73 | 2.61 | -- | 0.00 | -- | 3.55 | 8.85 | 200.38 | -- | -3.24 | -- |
| Rapport Therapeutics Inc | 0.00 | -97.70m | 1.33bn | 69.00 | -- | 2.60 | -- | -- | -2.71 | -2.71 | 0.00 | 10.74 | 0.00 | -- | -- | 0.00 | -22.55 | -- | -23.12 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -125.11 | -- | -- | -- |
| Trevi Therapeutics Inc | 0.00 | -45.86m | 1.33bn | 26.00 | -- | 7.03 | -- | -- | -0.3713 | -0.3713 | 0.00 | 1.48 | 0.00 | -- | -- | 0.00 | -34.19 | -45.07 | -36.67 | -51.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -64.84 | -- | 31.21 | -- |
| Kodiak Sciences Inc | 0.00 | -217.34m | 1.35bn | 123.00 | -- | 49.37 | -- | -- | -4.12 | -4.12 | 0.00 | 0.447 | 0.00 | -- | -- | 0.00 | -73.58 | -33.79 | -82.91 | -35.95 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 32.36 | -- | -1.75 | -- |
| Intellia Therapeutics Inc | 57.53m | -445.81m | 1.37bn | 403.00 | -- | 1.84 | -- | 23.90 | -4.27 | -4.27 | 0.5488 | 6.46 | 0.0548 | -- | 5.78 | 142,749.40 | -42.49 | -33.78 | -46.95 | -37.16 | -- | -- | -774.94 | -790.71 | -- | -- | 0.00 | -- | 59.55 | 6.07 | -7.86 | -- | -3.19 | -- |
| Novavax Inc | 1.06bn | 341.75m | 1.41bn | 952.00 | 4.84 | -- | 3.75 | 1.33 | 1.80 | 1.80 | 6.29 | -0.9643 | 0.7362 | 7.87 | 16.49 | 1,118,331.00 | 23.63 | -39.12 | 53.33 | -248.97 | 91.82 | -- | 32.10 | -67.41 | 2.24 | 17.15 | 2.66 | -- | -30.65 | 105.39 | 65.60 | -- | 47.71 | -- |
| Zenas Biopharma Inc | 15.00m | -189.90m | 1.42bn | 130.00 | -- | 5.67 | -- | 94.48 | -12.67 | -12.67 | 0.4565 | 4.65 | 0.0414 | -- | -- | 115,384.60 | -52.35 | -- | -60.38 | -- | -- | -- | -1,265.99 | -- | -- | -116.56 | 0.2709 | -- | -90.00 | -- | -322.87 | -- | -- | -- |
| Alvotech SA | 573.35m | 69.50m | 1.45bn | 1.01k | 22.17 | -- | 13.76 | 2.52 | 0.2093 | 0.2093 | 1.93 | -0.5671 | 0.434 | 1.53 | 4.30 | 567,111.80 | 5.26 | -- | 6.38 | -- | 55.59 | -- | 12.12 | -201.24 | 0.7376 | 2.57 | 1.16 | -- | 426.84 | 42.86 | 57.98 | -- | 47.91 | -- |
Data as of Feb 13 2026. Currency figures normalised to Evotec SE's reporting currency: US Dollar USD
5.02%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Wellington Management Co. LLPas of 30 Sep 2025 | 1.23m | 1.38% |
| DCF Capital LLCas of 31 Dec 2025 | 1.20m | 1.35% |
| WCM Investment Management LLCas of 31 Dec 2025 | 559.34k | 0.63% |
| ABC Arbitrage Asset Management SAas of 31 Dec 2025 | 554.29k | 0.62% |
| Wellington Management Canada ULCas of 30 Sep 2025 | 201.07k | 0.23% |
| Parametric Portfolio Associates LLCas of 31 Dec 2025 | 184.21k | 0.21% |
| Jane Street Capital LLCas of 31 Dec 2025 | 183.29k | 0.21% |
| Pitcairn Group LPas of 30 Sep 2025 | 161.77k | 0.18% |
| Citadel Securities LLCas of 30 Sep 2025 | 96.05k | 0.11% |
| LPL Financial LLCas of 31 Dec 2025 | 94.63k | 0.11% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
